Malignant mesothelioma
MONDO:0006292A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells. It is associated with exposure to asbestos.
Also known as: malignant mesothelial tumor, malignant mesothelial tumour, malignant mesothelioma, malignant mesothelioma (disease), malignant neoplasm of mesothelium, malignant neoplasm of the mesothelium, malignant tumor of mesothelium, malignant tumor of the mesothelium
2828 clinical trials for this condition and its sub-types, 37 tagged with Malignant mesothelioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Malignant mesothelioma
-
Malignant pleural mesothelioma 71 trials · 75 incl. sub-types
2 sub-types
- Pleural epithelioid mesothelioma 8 trials
- Pleural sarcomatoid mesothelioma 2 trials
-
Malignant peritoneal mesothelioma 13 trials
-
Malignant epithelioid mesothelioma 5 trials · 12 incl. sub-types
1 sub-type
- Pleural epithelioid mesothelioma 8 trials
-
Malignant biphasic mesothelioma 2 trials · 5 incl. sub-types
1 sub-type
- Pleural biphasic mesothelioma 4 trials
-
Diffused pleural mesothelioma 3 trials
-
Sarcomatoid mesothelioma 2 trials · 3 incl. sub-types
2 sub-types
- Pleural sarcomatoid mesothelioma 2 trials
- Lymphohistiocytoid mesothelioma 0 trials
-
Localized pleural mesothelioma 2 trials
-
Malignant pericardial mesothelioma 0 trials
-
Mesothelioma of the tunica vaginalis 0 trials
-
Ovarian malignant mesothelioma 0 trials
-
Pleural mesothelioma in situ 0 trials
-
New drug targets genetic weakness in mesothelioma tumors
Disease control Not yet recruitingThis phase 2 trial tests a drug called BMS-986504 in 30 people with relapsed mesothelioma whose tumors have a specific genetic marker (MTAP deficiency). The drug aims to shrink tumors by blocking a protein cancer cells need to grow. Researchers will measure how many patients have…
Phase 2 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New immune cocktail takes on deadly mesothelioma
Disease control Not yet recruitingThis phase 2 trial tests whether adding two immune-boosting drugs (iparomlimab and tovorilimab) to standard chemotherapy and bevacizumab can shrink tumors in people with advanced mesothelioma who have not had prior treatment. About 37 participants will receive the combination eve…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase 1/2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC